DPP4 and diabetic kidney disease: In diabetic nephropathy, the miRNA-29 family protects the kidney from fibrotic damage, and the DPP-4 inhibitor linagliptin has been shown to inhibit TGF-β-induced endothelial to mesenchymal transition (EndMT) by restoring the miRNA-29s’ levels [64].